Henry Schein (HSIC) Q3 2026 Earnings Call Transcript

Henry Schein reported Q3 global sales of $3.5 billion, up 4.0%, and adjusted non-GAAP diluted EPS of $1.37, up 19.1% excluding a $0.19-per-share tariff-refund benefit and a $0.23 prior-year remeasurement gain. The company raised 2026 non-GAAP diluted EPS guidance to $5.50–$5.56 from $5.29–$5.39, while keeping sales-growth guidance at 4.5%–5.5%; adjusted EBITDA growth is now expected in the high single digits. US dental merchandise sales grew 8.6%, primarily on volume, and Henry Schein repurchased $125 million of shares in the quarter. Management cited pressure in discretionary procedures and Brazil, while maintaining its expectation of double-digit earnings growth in 2027.

Analysis

The more durable signal is volume-led US dental share capture—not the EPS beat. If company-brand and exclusive-product gains persist, HSIC may improve customer retention and purchasing share while creating distribution for software and implants. That mix could support earnings beyond the tariff benefit; however, the reported improvement is not yet proof of a sustainably higher margin profile. A modest operating-margin expansion alongside management’s large savings commitment leaves execution, not the target, as the key underwriting question.

The near-term risk is that investors capitalize management’s 2027 double-digit EPS aspiration before seeing a clean base: the current-year outlook includes a non-recurring tariff-refund contribution, and Q4 growth investments may temper earnings. Unchanged sales guidance despite higher EPS reinforces the need to separate operating leverage from one-offs. Management’s commentary on selective procedure deferrals, Brazil, and weak point-of-care diagnostics also argues against extrapolating broad-based end-market acceleration. CFO transition and cash conversion deserve monitoring; quarterly operating cash flow below net income may reflect timing, but needs full-year confirmation.

Over 1–3 months, test whether US dental merchandise volume/share gains continue and whether margin benefits reach reported results after Q4 investment. Over 6–18 months, cloud adoption and shared-services execution could deepen customer relationships and lift mix, but customer additions alone do not establish subscription economics or reduced churn. Patterson Companies and other dental distributors could face share pressure if these gains are sustained; suppliers may face stronger private-label substitution. Contrarian read: the market may treat the raised EPS outlook as cleaner than it is, while underweighting the option value of durable share gains. No valuation or consensus data support a price target or an aggressive event trade.

Key Decisions for Investors

• Favor a measured HSIC long on post-earnings weakness rather than chasing the headline EPS increase. Add only if subsequent reporting confirms continued volume-led US dental growth and margin conversion; thesis is falsified by a material reversal in dental merchandise growth or failure to deliver operating-income savings.
• Do not annualize the tariff-related EPS benefit. Rebuild the earnings base excluding the disclosed benefit and compare future guidance with that normalized base; treat management’s 2027 growth comments as an aspiration until formal guidance and results substantiate it.
• Monitor Q4 investment spend against customer activation and share-of-wallet evidence, plus cloud subscription retention/monetization—not just net customer adds. If spending rises without improved growth or margins, reduce exposure to the operating-leverage thesis.
• Track full-year operating cash flow versus earnings and the incoming CFO’s capital-allocation priorities before assuming buybacks are a durable earnings tailwind. Weak cash conversion or a material deterioration in Brazil, point-of-care diagnostics, or discretionary procedure demand would weaken the long case.